Skip to main content
. 2022 Jul 7;13(4):e01612-22. doi: 10.1128/mbio.01612-22

FIG 2.

FIG 2

Pharmacokinetic characterization of G12 antibody in vivo after i.v. administration of antibodies or mRNA-LNPs. The remaining G12 antibodies in the serum were monitored for 7 days. (A) G12-scFv; (B) G12-scFv-Fc; (C) G12-IgG; (D) mL (G12-scFv); (E) mL (G12-scFv-Fc); (F) mL (G12-IgG).